MPM CAPITAL

MPM Capital is a healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical

TEAM MEMBER ARCHIVE

All Investment and Operations Team Executive Partners and Advisors Medical and Scientific Advisory Board ED HURWITZ, J.D., M.B.A. Ed Hurwitz, an accomplished biotech executive and investor, is a Managing Director at MPM Capital. Ed serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics and is on the board of Dyne Therapeutics (NASDAQ: DYN). Prior to MPM, he was founder and Managing Director of Precision BioVentures where he

founded and seeded

TURMERIC ACQUISITION CORP. Turmeric Acquisition Corp. is a special purpose acquisition company (SPAC) that raised $85M in its initial public offering in October 2020. The company is listed on the Nasdaq with the common shares trading under the symbol “TMPM” and is targeting a merger with a biopharmaceutical company developing novel therapies for its initial business combination. MATTHEW RODEN, PH.D. Dr. Matthew Roden is the President and CEO and serves on the board of Aktis Oncology, an MPM portfolio company. Matt also serves as Chairman of Turmeric Acquisition Corporation (NASDAQ: TMPM), and on the Boards of Directors of iTeos Therapeutics (NASDAQ: ITOS) and NextPoint Therapeutics, all MPM portfolio companies. Prior to joining MPM,

Matt’s career

WILLIAM C. HAHN, M.D., PH.D. William (Bill) C. Hahn, MD, PhD, is both a leading scientist and physician involved in biomedical research and in the care of cancer patients. He joined the OIF Advisory Board in 2017 to help MPM continue to translate scientific innovations in oncology into positive

clinical outcomes.

ELIZABETH STONER, M.D. Dr. Elizabeth (Liz) Stoner is the Senior Clinical Advisor of AlloVir (NASDAQ: ALVR), an ElevateBio company, and was most recently the company’s interim CMO. She also serves as Senior Clinical Advisor to Rhythm Pharmaceuticals (NASDAQ: RYTM). Liz is a distinguished biopharma executive, who brings decades of international industry

experience to

SHINICHIRO FUSE, PH.D. Shinichiro (Shin) Fuse, Ph.D., joined MPM as a Principal in 2016 and is engaged in MPM’s investment identification, due diligence and business development activities MITCHELL H. FINER, PH.D. Mitchell (Mitch) H. Finer, Ph.D., joined MPM Capital as Managing Director in mid-2015. Since then he has founded Oncorus Inc, focused on the development of Oncolytic herpes viruses for the treatment of GBM and other malignancies, where he serves as CEO and CSO.

LEIGH ZAWEL, PH.D.

Leigh Zawel joined MPM in 2017 as a Managing Director. An oncology expert with significant pharmaceutical experience overseeing large and small molecule projects, Leigh will provide invaluable insight into MPM’s investment due-diligence process and operational guidance to support the firm’s company-building

MPM CAPITAL

MPM Capital is a healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical

TEAM MEMBER ARCHIVE

All Investment and Operations Team Executive Partners and Advisors Medical and Scientific Advisory Board ED HURWITZ, J.D., M.B.A. Ed Hurwitz, an accomplished biotech executive and investor, is a Managing Director at MPM Capital. Ed serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics and is on the board of Dyne Therapeutics (NASDAQ: DYN). Prior to MPM, he was founder and Managing Director of Precision BioVentures where he

founded and seeded

TURMERIC ACQUISITION CORP. Turmeric Acquisition Corp. is a special purpose acquisition company (SPAC) that raised $85M in its initial public offering in October 2020. The company is listed on the Nasdaq with the common shares trading under the symbol “TMPM” and is targeting a merger with a biopharmaceutical company developing novel therapies for its initial business combination. MATTHEW RODEN, PH.D. Dr. Matthew Roden is the President and CEO and serves on the board of Aktis Oncology, an MPM portfolio company. Matt also serves as Chairman of Turmeric Acquisition Corporation (NASDAQ: TMPM), and on the Boards of Directors of iTeos Therapeutics (NASDAQ: ITOS) and NextPoint Therapeutics, all MPM portfolio companies. Prior to joining MPM,

Matt’s career

WILLIAM C. HAHN, M.D., PH.D. William (Bill) C. Hahn, MD, PhD, is both a leading scientist and physician involved in biomedical research and in the care of cancer patients. He joined the OIF Advisory Board in 2017 to help MPM continue to translate scientific innovations in oncology into positive

clinical outcomes.

ELIZABETH STONER, M.D. Dr. Elizabeth (Liz) Stoner is the Senior Clinical Advisor of AlloVir (NASDAQ: ALVR), an ElevateBio company, and was most recently the company’s interim CMO. She also serves as Senior Clinical Advisor to Rhythm Pharmaceuticals (NASDAQ: RYTM). Liz is a distinguished biopharma executive, who brings decades of international industry

experience to

SHINICHIRO FUSE, PH.D. Shinichiro (Shin) Fuse, Ph.D., joined MPM as a Principal in 2016 and is engaged in MPM’s investment identification, due diligence and business development activities MITCHELL H. FINER, PH.D. Mitchell (Mitch) H. Finer, Ph.D., joined MPM Capital as Managing Director in mid-2015. Since then he has founded Oncorus Inc, focused on the development of Oncolytic herpes viruses for the treatment of GBM and other malignancies, where he serves as CEO and CSO.

LEIGH ZAWEL, PH.D.

Leigh Zawel joined MPM in 2017 as a Managing Director. An oncology expert with significant pharmaceutical experience overseeing large and small molecule projects, Leigh will provide invaluable insight into MPM’s investment due-diligence process and operational guidance to support the firm’s company-building IMPACT - MPM CAPITAL Making an Impact Through Innovation MPM continuously seeks new ways to invest in order to drive breakthroughs and cures, and two of its investment vehicles feature innovative social impact components: The first is the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM that

donates a portion

THOMAS M. BARNES, PH.D. Dr. Thomas (Tom) M. Barnes is the CEO of Orna Therapeutics, an MPM portfolio company. Tom is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations, having led platform-based research and drug discovery teams for over 20 years. Tom has co-founded or helped launch several companies, NICHOLAS MCGRATH, J.D., LL.M. Nicholas McGrath is the General Counsel and Chief Compliance Officer at MPM Capital. His primary responsibility is to oversee the firm’s legal and compliance program. Prior to joining MPM, Nick served as the General Counsel and Chief Compliance Officer at a Boston-based healthcare and biotech investment adviser, where he was responsible for managing the legal, DAVID BREDT, M.D., PH.D. Dr. David S. Bredt is a proven leader in neurology research and development and has held key senior roles at Eli Lilly and Company and Johnson & Johnson. Before joining MPM, David was Site Head for Johnson & Johnson’s R&D Campus in La Jolla, which focuses on Neuroscience, Immunology and Biotechnology and is the original

DAN HICKLIN, PH.D.

Executive Partners. Dr. Dan Hicklin currently serves as an MPM Advisor and is Founder and CEO of Werewolf Therapeutics, an MPM portfolio company. Dan is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience. He also serves as President of Trieza Therapeutics and is a

GARY PATOU, M.D.

Gary has served as interim Chief Medical Officer in various MPM portfolio companies, including Pacira Pharmaceuticals (PCRX) and Peplin, Ltd., where he took a leading role in gaining FDA approval for Exparel® and Picato®, respectively.

LEIGH ZAWEL, PH.D.

Leigh Zawel joined MPM in 2017 as a Managing Director. An oncology expert with significant pharmaceutical experience overseeing large and small molecule projects, Leigh will provide invaluable insight into MPM’s investment due-diligence process and operational guidance to support the firm’s company-building

HYPNION, INC.

Hypnion Inc. is a wholly owned subsidiary of Eli Lilly and Company(www.lilly.com). We are focused on the development of novel therapeutics for the treatment of central nervous system (CNS) disorders to serve the vastly underserved markets of sleep and

wake-alertness

GREG SIECZKIEWICZ, J.D., PH.D. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the U.S. Patent and Trademark Office. He is also the former President of the Boston Patent Law Association. Greg received his J.D., magna cum laude, from the evening program of Suffolk University Law School and earned his Ph.D. in Cell, Molecular VINAY BHASKAR, PH.D. Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck and Xencor.

MPM CAPITAL

MPM Capital is a healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical

TEAM MEMBER ARCHIVE

All Investment and Operations Team Executive Partners and Advisors Medical and Scientific Advisory Board ED HURWITZ, J.D., M.B.A. Ed Hurwitz, an accomplished biotech executive and investor, is a Managing Director at MPM Capital. Ed serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics and is on the board of Dyne Therapeutics (NASDAQ: DYN). Prior to MPM, he was founder and Managing Director of Precision BioVentures where he

founded and seeded

TURMERIC ACQUISITION CORP. Turmeric Acquisition Corp. is a special purpose acquisition company (SPAC) that raised $85M in its initial public offering in October 2020. The company is listed on the Nasdaq with the common shares trading under the symbol “TMPM” and is targeting a merger with a biopharmaceutical company developing novel therapies for its initial business combination. NICHOLAS MCGRATH, J.D., LL.M. Nicholas McGrath is the General Counsel and Chief Compliance Officer at MPM Capital. His primary responsibility is to oversee the firm’s legal and compliance program. Prior to joining MPM, Nick served as the General Counsel and Chief Compliance Officer at a Boston-based healthcare and biotech investment adviser, where he was responsible for managing the legal, SHINICHIRO FUSE, PH.D. Shinichiro (Shin) Fuse, Ph.D., joined MPM as a Principal in 2016 and is engaged in MPM’s investment identification, due diligence and business development activities WILLIAM C. HAHN, M.D., PH.D. William (Bill) C. Hahn, MD, PhD, is both a leading scientist and physician involved in biomedical research and in the care of cancer patients. He joined the OIF Advisory Board in 2017 to help MPM continue to translate scientific innovations in oncology into positive

clinical outcomes.

ELIZABETH STONER, M.D. Dr. Elizabeth (Liz) Stoner is the Senior Clinical Advisor of AlloVir (NASDAQ: ALVR), an ElevateBio company, and was most recently the company’s interim CMO. She also serves as Senior Clinical Advisor to Rhythm Pharmaceuticals (NASDAQ: RYTM). Liz is a distinguished biopharma executive, who brings decades of international industry

experience to

MITCHELL H. FINER, PH.D. Mitchell (Mitch) H. Finer, Ph.D., joined MPM Capital as Managing Director in mid-2015. Since then he has founded Oncorus Inc, focused on the development of Oncolytic herpes viruses for the treatment of GBM and other malignancies, where he serves as CEO and CSO. VINAY BHASKAR, PH.D. Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck and Xencor.

MPM CAPITAL

MPM Capital is a healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical

TEAM MEMBER ARCHIVE

All Investment and Operations Team Executive Partners and Advisors Medical and Scientific Advisory Board ED HURWITZ, J.D., M.B.A. Ed Hurwitz, an accomplished biotech executive and investor, is a Managing Director at MPM Capital. Ed serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics and is on the board of Dyne Therapeutics (NASDAQ: DYN). Prior to MPM, he was founder and Managing Director of Precision BioVentures where he

founded and seeded

TURMERIC ACQUISITION CORP. Turmeric Acquisition Corp. is a special purpose acquisition company (SPAC) that raised $85M in its initial public offering in October 2020. The company is listed on the Nasdaq with the common shares trading under the symbol “TMPM” and is targeting a merger with a biopharmaceutical company developing novel therapies for its initial business combination. NICHOLAS MCGRATH, J.D., LL.M. Nicholas McGrath is the General Counsel and Chief Compliance Officer at MPM Capital. His primary responsibility is to oversee the firm’s legal and compliance program. Prior to joining MPM, Nick served as the General Counsel and Chief Compliance Officer at a Boston-based healthcare and biotech investment adviser, where he was responsible for managing the legal, SHINICHIRO FUSE, PH.D. Shinichiro (Shin) Fuse, Ph.D., joined MPM as a Principal in 2016 and is engaged in MPM’s investment identification, due diligence and business development activities WILLIAM C. HAHN, M.D., PH.D. William (Bill) C. Hahn, MD, PhD, is both a leading scientist and physician involved in biomedical research and in the care of cancer patients. He joined the OIF Advisory Board in 2017 to help MPM continue to translate scientific innovations in oncology into positive

clinical outcomes.

ELIZABETH STONER, M.D. Dr. Elizabeth (Liz) Stoner is the Senior Clinical Advisor of AlloVir (NASDAQ: ALVR), an ElevateBio company, and was most recently the company’s interim CMO. She also serves as Senior Clinical Advisor to Rhythm Pharmaceuticals (NASDAQ: RYTM). Liz is a distinguished biopharma executive, who brings decades of international industry

experience to

MITCHELL H. FINER, PH.D. Mitchell (Mitch) H. Finer, Ph.D., joined MPM Capital as Managing Director in mid-2015. Since then he has founded Oncorus Inc, focused on the development of Oncolytic herpes viruses for the treatment of GBM and other malignancies, where he serves as CEO and CSO. VINAY BHASKAR, PH.D. Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck and Xencor. BRIGGS MORRISON, M.D. Dr. Briggs W. Morrison is the CEO and a Board Director of Syndax Pharmaceuticals (NASDAQ: SNDX), an MPM portfolio company. Briggs serves on the board of MPM portfolio companies Oncorus (NASDAQ: ONCR), Repare Therapeutics (NASDAQ: RPTX), Twentyeight-Seven Therapeutics and Werewolf Therapeutics. Briggs is also an investment committee member of the UBS Oncology Impact Fund THOMAS M. BARNES, PH.D. Dr. Thomas (Tom) M. Barnes is the CEO of Orna Therapeutics, an MPM portfolio company. Tom is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations, having led platform-based research and drug discovery teams for over 20 years. Tom has co-founded or helped launch several companies,

KELLIE NEVILLE

Kellie Neville is the Director of Investor Relations at MPM Capital. She joins MPM’s Managing Directors in building lasting relationships with its Limited Partners. Kellie also leads MPM’s communications and marketing efforts. Prior to joining MPM, Kellie was Director of Investor Relations & Marketing at 424 Capital, a boutique private

DAN HICKLIN, PH.D.

Executive Partners. Dr. Dan Hicklin currently serves as an MPM Advisor and is Founder and CEO of Werewolf Therapeutics, an MPM portfolio company. Dan is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience. He also serves as President of Trieza Therapeutics and is a GREG SIECZKIEWICZ, J.D., PH.D. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the U.S. Patent and Trademark Office. He is also the former President of the Boston Patent Law Association. Greg received his J.D., magna cum laude, from the evening program of Suffolk University Law School and earned his Ph.D. in Cell, Molecular DAVID BREDT, M.D., PH.D. Dr. David S. Bredt is a proven leader in neurology research and development and has held key senior roles at Eli Lilly and Company and Johnson & Johnson. Before joining MPM, David was Site Head for Johnson & Johnson’s R&D Campus in La Jolla, which focuses on Neuroscience, Immunology and Biotechnology and is the original

TODD FOLEY, M.B.A.

Todd Foley is a Managing Director at MPM Capital. He focuses on biotech investments and serves on a number of MPM portfolio company boards, including Repare Therapeutics, CODA Biotherapeutics, Chiasma (CHMA), Iconic, Rhythm (RYTM), Semma and Tetherex. CHRISTIANA BARDON, M.D., M.B.A. Christiana Bardon, M.D. joined in 2015 as a managing director of the UBS Oncology Impact Fund (OIF) managed by MPM. Chris is the founder and managing member of Burrage Capital, a long short hedge fund in biotechnology and healthcare.

LEIGH ZAWEL, PH.D.

Leigh Zawel joined MPM in 2017 as a Managing Director. An oncology expert with significant pharmaceutical experience overseeing large and small molecule projects, Leigh will provide invaluable insight into MPM’s investment due-diligence process and operational guidance to support the firm’s company-building MPM CARL WEISSMAN 203PX X 233PX MPM carl weissman 203px X 233px. Published October 15, 2014 at 203 × 233 in MPM carl weissman 203px X 233px.

__ Investor Login

* Home

* About

* Companies

* Team

* Contact

* Press

*

SEARCH __

MPM FOCUS AREA

ANTIBODY AGENTS FOR THE TREATMENT OF CANCER

Learn More

About

OUR FOCUS

MPM Capital is a healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical breakthroughs that transform patients’ lives. MAKING AN IMPACT THROUGH INNOVATION MPM continuously seeks new ways to invest in order to drive breakthroughs and cures, and two of its investment vehicles feature innovative social impact components: * The first is the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM that donates a portion of profits and royalties to cancer care and research. Since 2018, MPM has donated approximately $7 million of its profits (carried interest) split equally between donations to the American Association of Cancer Research to support research for potential future transformative therapies and donations to the UBS Optimus Foundation to support emerging market access to cancer care. * The second features a philanthropy-investment opportunity involving Dana-Farber Cancer Institute (DFCI) to advance cancer research. This unique philanthropy-investment opportunity gives MPM early insight into DFCI projects with commercial potential and provides DFCI with potential new philanthropic resources.

FOCUS AREA

All Oncology Other

INVESTMENTS

Current Exited

EXIT TYPE

All IPO M&A

*

23ANDME

Genetic reports for consumers to better appreciate their ancestry

* Other

* Exited

28-7

Small-molecule therapeutics that modulate miRNAs for treatment

* Oncology

* Current

AFFYMAX, INC.

Previously committed to developing novel drugs

* Other

* Exited

AIRES

Clinical stage pharmaceutical company for pulmonary disorders

* Other

* Exited

ALINEA PHARMACEUTICALS, INC. Previously developed new treatments for metabolic conditions

* Other

* Exited

ALLOZYNE, INC.

Cancer and inflammatory disease therapeutic company

* Other

* Exited

ALNARA

Orally-delivered protein therapeutics to treat metabolic diseases

* Other

* Exited

AMPHIVENA

Developing bispecific TandAbs as a novel immunotherapy for hematological disorders

* Oncology

* Current

ANTHERA

Developing drugs for autoimmune diseases

* Other

* Exited

ARCHUS ORTHOPEDICS, INC. Previously developed implants to treat spine disorders

* Other

* Exited

ARYX THERAPEUTICS, INC. Previously focused on molecular design

* Other

* Exited

ASTUTE MEDICAL

Improving the diagnosis of high-risk medical conditions

* Other

* Exited

ATOPIX THERAPEUTICS, INC. Developing novel treatments for asthma

* Other

* Exited

BARRIER THERAPEUTICS, INC. Specialized in dermatological creams and gels

* Other

* Exited

BIOINTERVENE

First-in-class target for the treatment of neuropathic pain

* Other

* Current

BLADE THERAPEUTICS

A discovery stage company focused on developing fibrosis treatments

* Other

* Current

CELLADON

Developing a transformative therapy for heart failure

* Other

* Exited

CELLERANT THERAPEUTICS, INC. novel immunotherapies for oncology and blood-related disorders

* Oncology

* Exited

CERECOR INC.

Developing innovative treatments for patients with CNS disorders

* Other

* Exited

CEREGENE, INC.

Development and manufacturing of gene therapies

* Other

* Exited

CERIMON PHARMACEUTICALS, INC. Developed and commercialized therapeutics for autoimmune diseases

* Other

* Exited

CHF SOLUTIONS, INC.

Manufactures medical devices for cardiac care.

* Other

* Exited

CHIASMA

Developing oral drugs that were previously only available by injection

* Other

* Current

CLINICAL INK

Modernize clinical trials with eSource & patient engagement tools

* Other

* Exited

CODA BIOTHERAPEUTICS Chemogenetic neuromodulation platform to treat neurological disorders.

* Other

* Current

CONATUS

Developing novel therapeutics for liver diseases

* Other

* Exited

COSTIM

Developing novel antibodies for cancer immunotherapy

* Oncology

* Exited

COTHERIX, INC.

Licensing of therapeutic products for cardiopulmonary diseases

* Other

* Exited

CULLINAN MANAGEMENT

Creating high-value cancer therapies using modern-day portfolio manage

* Oncology

* Current

DIGITX PARTNERS

DigiTx Partners is a digital health investment formed in partnership with Astellas Pharma

* Other

* Current

DRAGONFLY SCIENCES, INC. developing a new class of biosimilar products

* Other

* Exited

DYNE THERAPEUTICS

Developing a pipeline of RNA-based therapeutics for neuromuscular

disorders

* Other

* Current

EKR THERAPEUTICS

Provides acute-care specialty products

* Other

* Exited

ELEVATEBIO, LLC

Building a broad portfolio of cell and gene therapy companies

* Oncology

* Current

ELIXIR PHARMACEUTICALS, INC. Develops novel pharmaceuticals for the treatment of metabolic diseases

* Other

* Exited

ENDOGASTRIC SOLUTIONS, INC. Endoluminal treatment of gastroesophageal reflux disease

* Other

* Exited

ENDOLOGIX

Provides optimal solutions for endovascular aortic repair

* Other

* Exited

ENTEROMEDICS, INC.

developer of vBloc® neurometabolic therapy

* Other

* Exited

ENTRADA THERAPEUTICS Developing intracellular biologics for diseases with limited or no

treatment options

* Other

* Current

EPIZYME

Personalized therapeutics for patients with genetically defined cancer

* Oncology

* Exited

FORTEBIO

Develops analytical systems that enable real-time analysis of biomolecular interactions

* Other

* Exited

FRONTIER MEDICINES

Developing novel medicines to drug previously considered “undruggable” targets

* Oncology

* Current

HARPOON THERAPEUTICS T cell redirecting antibodies for durable remissions in cancer

* Oncology

* Current

HELICOS BIOSCIENCES CORPORATION Genetic analysis for the research, drug discovery and diagnostics

* Other

* Exited

HYPNION, INC.

development of novel therapeutics for (CNS) disorders

* Other

* Exited

ICONIC

Developing therapeutics for serious eye disorders

* Oncology

* Other

* Current

IDUN PHARMACEUTICALS, INC.

* Other

* Exited

INNOVATIVE SPINAL TECHNOLOGIES, INC. Developed treatments for spinal disorders

* Other

* Exited

INTERCELL AG

Modern prophylactic and therapeutic vaccines

* Other

* Exited

INTRACEL HOLDINGS CORPORATION Development and commercialization of cancer vaccines

* Oncology

* Exited

IOMX THERAPEUTICS AG Targeting T cell evasion to treat cancer

* Oncology

* Current

IPIERIAN

Developing anti-Tau protein antibodies for neurodegenerative disease

* Other

* Exited

ITEOS THERAPEUTICS

Next-gen immuno-oncology therapies for both hot and cold tumors

* Oncology

* Current

KALOBIOS PHARMACEUTICALS, INC. developing monoclonal antibodies for cancer care

* Oncology

* Exited

MACROGENICS, INC.

* Oncology

* Exited

MAVERICK THERAPEUTICS, INC. Inducible T cell-redirecting antibodies for cancer

* Oncology

* Current

MEMORY PHARMACEUTICALS CORP. Developed drug candidates for the treatment of CNS disorders

* Other

* Exited

MERITAGE PHARMA

Treatment for eosinophilic esophagitis (EoE)

* Other

* Exited

MITOBRIDGE

Discovers and develops novel drugs that enhance mitochondrial function

* Other

* Exited

MOTUS THERAPEUTICS, INC. Developing therapies for severe gastric mobility disorders

* Other

* Exited

NEOSIL

Manufactures dermatology-focused specialty pharmaceutical products

* Oncology

* Exited

NEOVISTA, INC.

Technologies for age related mucular degeneration

* Other

* Exited

NEUROMED PHARMACEUTICALS, INC. Produces pain therapies in the US

* Other

* Exited

NEVRO

Developing a high-frequency stimulation technology for chronic pain

* Other

* Exited

ONCORUS

Developing a next-generation immunotherapy platform to treat cancer

* Oncology

* Current

OXAGEN LIMITED

A privately-held biopharmaceutical company

* Other

* Exited

PACIRA

Acute care products including EXPAREL for post-surgical analgesia

* Other

* Exited

PEPLIN

Products for the treatment of cancer

* Oncology

* Exited

PEPTIMMUNE, INC.

Designs peptides for therapeutics, diagnostic kits & antibodies

* Other

* Exited

PHARMASSET

Discovering and developing novel drugs to treat viral infections

* Other

* Exited

PHARMATHENE, INC.

Acquire and develop products identified as urgent priorities

* Other

* Exited

PONIARD PHARMACEUTICALS, INC. Discovery, development and commercialization of oncology products

* Other

* Exited

PORTOLA PHARMACEUTICALS, INC. A biopharmaceutical company in the hematologic diseases fields

* Other

* Exited

POTENZA THERAPEUTICS Developing novel immunotherapies for the treatment of cancer

* Oncology

* Exited

PROTEON THERAPEUTICS Developing a therapy to improve dialysis vascular access

* Other

* Exited

QUATRX PHARMACEUTICALS COMPANY Treatment of moderate to severe dyspareunia FDA approved in Feb 2013

* Other

* Exited

RADIUS HEALTH

Novel, differentiated therapeutics for patients with osteoporosis

* Other

* Exited

RAZE THERAPEUTICS

Developing novel anti-tumor agents through mitochondrial one-carbon me

* Oncology

* Exited

RECODE

Integrated genetic medicines company

* Other

* Current

REPARE THERAPEUTICS

Targeting genetically-defined cancer weaknesses

* Oncology

* Current

RHYTHM

Developing peptide therapeutics for metabolic diseases

* Other

* Current

RIGEL PHARMACEUTICALS, INC. Small-molecule development for inflammatory and autoimmune diseases

* Oncology

* Exited

RINAT NEUROSCIENCE CORP. Develops treatment of diseases and disorders of the nervous system

* Other

* Exited

SAI

Drug discovery, development, and manufacturing services

* Other

* Exited

SELEXYS

Developing novel products to treat inflammatory diseases

* Other

* Exited

SEMMA THERAPEUTICS

Developing cell-based transformative therapies for diabetes patients

* Other

* Exited

SIDERIS PHARMACEUTICALS, INC. Development of new treatments for transfusion related iron overload

* Other

* Exited

SIO2 MEDICAL PRODUCTS Novel materials science technology for pharmaceutical, lab and

diagnostic products

* Other

* Current

SOLASIA

Developing, commercializing oncology & oncology supportive care drugs

* Oncology

* Exited

SOMAXON PHARMACEUTICALS, INC. Developed Silenor for treatment of insomnia

* Other

* Exited

SURFACE LOGIX, INC.

Enhancing molecular functionality of pharmaceuticals

* Other

* Exited

SYNDAX

Developing and commercializing epigenetic therapies for cancer

* Oncology

* Current

TCR2, INC.

Focused on engineering T cells for cancer therapy

* Oncology

* Current

TERCICA, INC.

Developed Increlex for treatment of primary IGF-1 deficiency

* Other

* Exited

TETHEREX PHARMACEUTICALS Operates in the healthcare industry focusing on biotechnology business

* Other

* Current

THERACLONE SCIENCES, INC. Screening technology for antibodies that ward off disease

* Other

* Exited

TIZONA THERAPEUTICS, INC. Regulatory T cell suppression as a novel approach to fighting cancer

* Oncology

* Current

TRINETX

Platform to improve clinical research, study design & recruitment

* Other

* Exited

TRIPLET THERAPEUTICS Developing novel therapies for triplet repeat disorders

* Other

* Current

TRISHULA

Developing a first-in-class anti-CD39 antibody for treating cancer.

* Oncology

* Other

* Current

TRUE NORTH THERAPEUTICS Developing drugs which selectively inhibit the complement system

* Other

* Exited

TURMERIC ACQUISITION CORP. Turmeric Acquisition Corp. is a special purpose acquisition company

(SPAC).

* Current

VACCINOGEN, INC.

Personalized vaccines to fight disease

* Oncology

* Other

* Exited

VALERITAS

Marketing a disposable insulin delivery device

* Other

* Exited

VASCULAR

Developing a novel antibody for diabetic nephropathy

* Other

* Exited

VERASTEM, INC.

Treating cancer by the targeted killing of cancer stem cells

* Oncology

* Exited

VERUS PHARMACEUTICALS, INC. Pediatric-oriented specialty pharmaceutical company

* Other

* Exited

VLST CORPORATION

Novel therapeutics for autoimmunity and inflammation

* Other

* Exited

WEREWOLF THERAPEUTICS Novel immunotherapies that act selectively to enhance immune responses

to cancer

* Oncology

* Current

XANODYNE PHARMACEUTICALS, INC. Integrated specialty pharmaceutical company

* Other

* Exited

ROLE

All Investment Team Executive Partners and Entrepreneurs Advisors

Operations Team

LOCATION

All Cambridge San Francisco

*

PATRICK A. BAEUERLE

PATRICK A. BAEUERLE, PH.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

CHRIS BARDON

CHRISTIANA BARDON, M.D., M.B.A.

Cambridge

Read Bio

THOMAS M. BARNES

THOMAS M. BARNES, PH.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

VINAY BHASKAR

VINAY BHASKAR, PH.D.

San Francisco

Read Bio

DETLEV BINISZKIEWICZ DETLEV BINISZKIEWICZ, PH.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

STEPHEN BLACKLOW

STEPHEN C. BLACKLOW, M.D., PH.D.

ADVISOR

Cambridge

Read Bio

SCOTT CHAPPEL

SCOTT CHAPPEL, PH.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

STEPHEN CURTIS

STEPHEN CURTIS, PH.D.

Cambridge

Read Bio

THOMAS EBELING

THOMAS EBELING

ADVISOR

Read Bio

STEPHEN ELLEDGE

STEPHEN J. ELLEDGE, PH.D.

ADVISOR

Read Bio

LUKE EVNIN

LUKE EVNIN, PH.D.

San Francisco

Read Bio

MITCHELL FINER

MITCHELL H. FINER, PH.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

TODD FOLEY

TODD FOLEY, M.B.A.

Cambridge

Read Bio

SHINICHIRO FUSE

SHINICHIRO FUSE, PH.D.

Cambridge

Read Bio

ANSBERT GADICKE

ANSBERT GADICKE, M.D.

Cambridge

Read Bio

BRIAN GOODMAN

BRIAN GOODMAN, PH.D.

Cambridge

Read Bio

WILLIAM GREENE

WILLIAM GREENE, M.D.

ADVISOR

San Francisco

Read Bio

WILLIAM HAHN

WILLIAM C. HAHN, M.D., PH.D.

ADVISOR

Read Bio

DAVID HALLAL

DAVID HALLAL

ADVISOR

Cambridge

Read Bio

DAN HICKLIN

DAN HICKLIN, PH.D.

ADVISOR

Cambridge

Read Bio

ROBERT HORVITZ

H. ROBERT HORVITZ, PH.D.

ADVISOR

Read Bio

OWEN HUGHES

OWEN HUGHES

ADVISOR

Cambridge

Read Bio

ED HURWITZ

ED HURWITZ, J.D., M.B.A.

San Francisco

Read Bio

KRISTEN LAGUERRE, M.B.A.

KRISTEN LAGUERRE

CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER

Cambridge

Read Bio

TERRI LEE

TERRI LEE

San Francisco

Read Bio

NICHOLAS MCGRATH, J.D., LL.M.

NICHOLAS MCGRATH

GENERAL COUNSEL & CHIEF COMPLIANCE OFFICER

Cambridge

Read Bio

BRIGGS MORRISON

BRIGGS MORRISON, M.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

KELLIE NEVILLE

KELLIE NEVILLE

DIRECTOR OF INVESTOR RELATIONS

Cambridge

Read Bio

GARY PATOU

GARY PATOU, M.D.

ADVISOR

San Francisco

Read Bio

GERALDINE PAULUS

DR. GERALDINE PAULUS

SENIOR ASSOCIATE

Cambridge

Read Bio

DEVIN QUINLAN

DEVIN QUINLAN, PH.D.

Cambridge

Read Bio

MATTHEW RODEN

MATTHEW RODEN, PH.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

DAVID RYAN

DAVID P. RYAN, M.D.

ADVISOR

Read Bio

ANDREW SCHARENBERG

ANDREW M. SCHARENBERG, M.D.

EXECUTIVE PARTNER

San Francisco

Read Bio

GREG SIECZKIEWICZ

GREG SIECZKIEWICZ, J.D., PH.D. EXECUTIVE PARTNER & CHIEF IP COUNSEL

Cambridge

Read Bio

ELIZABETH STONER

ELIZABETH STONER, M.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

JON WIGGINTON, M.D.

JON WIGGINTON, M.D.

ADVISOR

Cambridge

Read Bio

LEIGH ZAWEL

LEIGH ZAWEL, PH.D.

EXECUTIVE PARTNER

Cambridge

Read Bio

CONTACT US

THE SAN FRANCISCO OFFICE HAS MOVED 1 MILE NORTH TO BRISBANE TO THE LOCATION SHOWN BELOW

info@mpmcapital.com

CAMBRIDGE, MA

450 Kendall Street

Cambridge, MA 02142

Phone | 617-425-9200

Get directions

BRISBANE, CA _ NEW ADDRESS _ 2000 Sierra Point Parkway, Suite 701

Brisbane, CA 94005

Phone | 650-553-3300

Get directions

Print Terms Of Use & Disclosures

* 2020

* 2019

* 2018

* 2017

* 2016

* 2015

* 2014

*

2020

November 30, 2020

RHYTHM PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF IMCIVREE™

November 19, 2020

UMOJA BIOPHARMA RAISES $53M IN SERIES A FINANCING

October 2, 2020

ONCORUS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

September 29, 2020

MPM JOINS THE HISTORIC SPAC BOOM AS ITS BLANK CHECK COMPANY FILES FOR

AN IPO

September 18, 2020

RODEN, FRESH FROM BMS-CELGENE MERGER, LANDS VC ROLE AT MPM

September 17, 2020

MPM CAPITAL BOLSTERS SENIOR TEAM WITH APPOINTMENT OF MATTHEW RODEN AS

EXECUTIVE PARTNER

September 17, 2020

AFTER LEADING CELGENE BUYOUT, MATTHEW RODEN LEAVES BRISTOL MYERS SQUIBB FOR VENTURE CAPITAL FIRM

September 16, 2020

DYNE THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

August 11, 2020

DYNE THERAPEUTICS ANNOUNCES $115 MILLION FINANCING TO ADVANCE PIPELINE OF MODERN OLIGONUCLEOTIDE THERAPEUTICS FOR SERIOUS MUSCLE DISEASES

July 30, 2020

ALLOVIR ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING

July 28, 2020

TCR² THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON

STOCK

July 24, 2020

ITEOS THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

July 21, 2020

GILEAD SCIENCES SECURES EXCLUSIVE OPTION TO ACQUIRE TIZONA THERAPEUTICS FOR $300 MILLION

July 16, 2020

ONCORUS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK

June 27, 2020

CHIASMA ANNOUNCES FDA APPROVAL OF MYCAPSSA® (OCTREOTIDE) CAPSULES, THE FIRST AND ONLY ORAL SOMATOSTATIN ANALOG

June 23, 2020

REPARE THERAPEUTICS ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC

OFFERING

June 6, 2020

CULLINAN ONCOLOGY COMPLETES $98.5 MILLION SERIES B FINANCING

June 1, 2020

AFTER INKING BRISTOL MYERS PACT, REPARE THERAPEUTICS SETS SIGHTS ON

IPO

May 28, 2020

REPARE THERAPEUTICS ANNOUNCES MULTI-TARGET DISCOVERY COLLABORATION WITH BRISTOL MYERS SQUIBB

April 1, 2020

ITEOS THERAPEUTICS CLOSES $125 MILLION SERIES B2 FINANCING

March 31, 2020

ELEVATEBIO CLOSES $170 MILLION SERIES B FINANCING

March 30, 2020

RECODE THERAPEUTICS RAISES $80 MILLION IN OVERSUBSCRIBED SERIES A

FINANCING

February 26, 2020

MPM CAPITAL ANNOUNCES $100M ONCOLOGY INNOVATIONS FUND AS PART OF NOVEL VENTURE PHILANTHROPY COLLABORATION WITH DANA-FARBER CANCER INSTITUTE

February 26, 2020

WSJ.COM – MPM CAPITAL RAISES $100 MILLION FUND, TEAMS UP WITH DANA-FARBER CANCER INSTITUTE

February 26, 2020

FIERCEBIOTECH – MPM GAINS FIRST OFFER ON DANA-FARBER TECH, RAISES

$100M FUND

February 26, 2020

ENDPOINTS NEWS – TYING BASIC SCIENCE TO SPINOUTS, DANA-FARBER DEBUTS SISTER FUNDS TOTALING $126M WITH MPM CAPITAL

February 24, 2020

AACR TO RECEIVE $2 MILLION TO SUPPORT INNOVATIVE RESEARCH FROM UBS ONCOLOGY IMPACT FUND MANAGED BY MPM CAPITAL

February 12, 2020

ALLOVIR RECEIVES THE EUROPEAN MEDICINES AGENCY PRIME DESIGNATION FOR VIRALYM-M, AN ALLOGENEIC, OFF-THE-SHELF, MULTI-VIRUS SPECIFIC T-CELL

THERAPY

February 7, 2020

DYNE THERAPEUTICS EXPANDS LEADERSHIP TEAM WITH KEY HIRES

February 5, 2020

CODA BIOTHERAPEUTICS ACQUIRES ATTENUA AND THREE CLINICAL STAGE ASSETS

January 30, 2020

ITEOS THERAPEUTICS AWARDED €15 MILLION IN NON-DILUTIVE FUNDING BY

THE WALLOON REGION

January 23, 2020

EPIZYME RECEIVES FDA ACCELERATED APPROVAL OF TAZVERIK™ (TAZEMETOSTAT) FOR THE TREATMENT OF EPITHELIOID SARCOMA

January 6, 2020

BIOINTERVENE ANNOUNCES $30 MILLION SERIES A FINANCING

*

2019

December 17, 2019

THE AACR-MPM ONCOLOGY CHARITABLE FOUNDATION ANNOUNCES FIRST GRANTS TO SUPPORT TRANSFORMATIVE CANCER RESEARCH

December 17, 2019

TRIPLET THERAPEUTICS LAUNCHES WITH $59 MILLION IN FINANCING TO FURTHER ITS DEVELOPMENT OF TRANSFORMATIVE TREATMENTS FOR TRIPLET REPEAT

DISORDERS

November 21, 2019

HARPOON THERAPEUTICS AND ABBVIE ANNOUNCE LICENSING AND OPTION COLLABORATION TO ADVANCE HPN217, HARPOONS’ BCMA-TARGETING TRITAC®, AND EXPAND EXISTING DISCOVERY COLLABORATION OVERALL DEAL POTENTIAL VALUED UP TO $2.4B

November 20, 2019

WEREWOLF THERAPEUTICS LAUNCHES WITH $56M SERIES A FINANCING TO DEVELOP TRANSFORMATIVE IMMUNO-STIMULATORY CANCER MEDICINES

November 18, 2019

NOVARTIS AND MPM CAPITAL INVEST IN SIO2 MEDICAL PRODUCTS DEVELOPING A POTENTIALLY DISRUPTIVE NOVEL PACKAGING TECHNOLOGY

November 15, 2019

NEW NOVARTIS MEDICINE ADAKVEO® (CRIZANLIZUMAB) APPROVED BY FDA TO REDUCE FREQUENCY OF PAIN CRISES IN INDIVIDUALS LIVING WITH SICKLE CELL

DISEASE

THERAPY DEVELOPED BY MPM PORTFOLIO COMPANY SELEXYS, ACQUIRED BY

NOVARTIS IN 2016

November 5, 2019

CODA BIOTHERAPEUTICS ANNOUNCES SERIES A EXTENSION, BRINGING TOTAL

ROUND TO $34M

October 16, 2019

RHYTHM PHARMACEUTICALS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING

October 8, 2019

MPM’S TODD FOLEY COMMENTS ON PHARMA MARKET IN WSJ PRO VC “PHARMA MERGERS, STRONG IPO MARKET MUTE STARTUP ACQUISITIONS”

October 7, 2019

TRINETX NAMED TECHNOLOGY PARTNER FOR FDA SENTINEL SYSTEM

September 25, 2019

BLADE THERAPEUTICS EXPANDS ANTI-FIBROTIC PIPELINE WITH ACQUISITION OF

ATXCO

September 24, 2019

MPM CAPITAL EXECUTIVE PARTNER PATRICK BAEUERLE WINS 2019 XCONOMY “X OF THE YEAR” AWARD

September 24, 2019

AMPHIVENA CLOSES $62 MILLION SERIES C FINANCING TO EXPAND THE CLINICAL DEVELOPMENT OF AMV564 INTO SOLID TUMORS AND TO DEVELOP ITS T CELL ENGAGEMENT PORTFOLIO

September 23, 2019

MPM CAPITAL PORTFOLIO COMPANY FRONTIER MEDICINES HONORED WITH A FIERCE

15 AWARD

September 4, 2019

MPM’S TODD FOLEY DISCUSSES ACQUISITION OF SEMMA THERAPEUTICS IN WSJ PRO VC “VERTEX MAKES ANOTHER AGGRESSIVE PURCHASE WITH SEMMA”

September 4, 2019

REPARE THERAPEUTICS ANNOUNCES US$82.5 MILLION SERIES B FINANCING

September 3, 2019

SEMMA THERAPEUTICS TO BE ACQUIRED BY VERTEX FOR $950M

August 22, 2019

ICONIC THERAPEUTICS SIGNS OPHTHALMOLOGY OPTION AGREEMENT WITH NOVARTIS

August 21, 2019

ONCORUS ANNOUNCES $79.5 MILLION SERIES B FINANCING TO SUPPORT THE ADVANCEMENT OF ONCOLYTIC VIRUS THERAPIES TO TRANSFORM OUTCOMES FOR

CANCER PATIENTS

July 26, 2019

CHIASMA ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF $55.0 MILLION OF COMMON STOCK

July 26, 2019

MGH AND ELEVATEBIO ANNOUNCE A 10-YEAR ALLIANCE AGREEMENT TO UTILIZE ELEVATEBIO BASECAMP TO MANUFACTURE INNOVATIVE CELL AND GENE THERAPIES

June 25, 2019

FRONTIER MEDICINES LAUNCHES WITH $67M SERIES A FINANCING DEVELOPING NOVEL MEDICINES THAT DRUG PREVIOUSLY CONSIDERED “UNDRUGGABLE” TARGETS, STARTING WITH CANCER

May 22, 2019

PORTFOLIO COMPANY ELEVATEBIO ANNOUNCES THAT ALLOVIR JOINS ITS PORTFOLIO OF HIGHLY INNOVATIVE CELL AND GENE THERAPY COMPANIES

May 16, 2019

ICONIC THERAPEUTICS AND EXELIXIS ENTER INTO EXCLUSIVE OPTION AND LICENSE AGREEMENT FOR NOVEL ANTIBODY-DRUG CONJUGATE PROGRAM

May 13, 2019

ELEVATEBIO LAUNCHES TO CREATE AND OPERATE A PORTFOLIO OF HIGHLY INNOVATIVE CELL AND GENE THERAPY COMPANIES $150M SERIES A FINANCING CO-LED BY UBS ONCOLOGY IMPACT FUND MANAGED BY

MPM CAPITAL

April 26, 2019

ARATANA THERAPEUTICS TO BE ACQUIRED BY ELANCO ANIMAL HEALTH

April 3, 2019

AACR-MPM ONCOLOGY CHARITABLE FOUNDATION TRANSFORMATIVE CANCER RESEARCH GRANTS PROGRAM NOW INVITING APPLICATIONS

April 3, 2019

DYNE THERAPEUTICS LAUNCHES WITH $50 MILLION SERIES A TO DEVELOP TARGETED THERAPIES FOR MUSCLE DISEASES

March 13, 2019

TRINETX SECURES $40 MILLION IN SERIES D FUNDING

February 22, 2019

MPM’S PATRICK A. BAEUERLE AWARDED THE 2019 LENNART PHILIPSON AWARD FOR CONTRIBUTIONS TO CANCER IMMUNOTHERAPY

February 22, 2019

BIOCENTURY: MPM KEEPS BUILDING LUKE EVNIN SPEAKS WITH CHRIS LIEU AT BIOCENTURY (FULL ARTICLE -

SUBSCRIPTION)

February 21, 2019

THE WALL STREET JOURNAL: BIOTECH INVESTOR MPM CAPITAL REFUELS WITH $400 MILLION VENTURE FUND ANSBERT GADICKE SPEAKS WITH BRIAN GORMLEY AT THE WALL STREET JOURNAL (FULL ARTICLE -SUBSCRIPTION)

February 21, 2019

SCRIP PHARMA INTELLIGENCE: MPM RAISES $400M TO BUILD EARLY-STAGE

BIOTECHS

ANSBERT GADICKE SPEAKS WITH KEVIN GROGAN AT SCRIP PHARMA INTELLIGENCE (FULL ARTICLE -SUBSCRIPTION)

February 21, 2019

ENDPOINTS NEWS: MPM ADDS $408M FOR ITS NEXT BIG WAVE OF BIOTECH STARTUPS — AND ONCOLOGY STILL DOMINATES THE MENU LUKE EVNIN SPEAKS WITH JOHN CARROLL AT ENDPOINTS NEWS

February 21, 2019

MPM CAPITAL RAISES $400 MILLION TO FUND EARLY-STAGE BIOTECH INNOVATION

February 20, 2019

HARVARD BUSINESS REVIEW: IMPACT INVESTING COULD ACCELERATE THE FIGHT

AGAINST

UBS ONCOLOGY IMPACT FUND MANAGED BY MPM CITED AS A “..MODEL OTHER FUNDS COULD EMULATE..”

January 3, 2019

TIZONA THERAPEUTICS APPOINTS SCOTT CLARKE AS CHIEF EXECUTIVE OFFICER AND PROVIDES UPDATE ON REGULATORY MILESTONE FOR ITS FIRST-IN-CLASS CD39 PROGRAM IN CANCER

January 3, 2019

TIZONA THERAPEUTICS AND ABBVIE ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP FIRST-IN-CLASS IMMUNOTHERAPY FOR CANCER TARGETING CD39

*

2018

December 18, 2018

ENTRADA THERAPEUTICS RAISES $59 MILLION SERIES A TO ADVANCE INTRACELLULAR BIOLOGICS PLATFORM SERIES A CO-LED BY 5AM VENTURES AND MPM CAPITAL, ALONG WITH OTHER TOP

INVESTORS

November 29, 2018

TCR2 THERAPEUTICS WINS U.S. PRIVATE COMPANY OF THE YEAR AWARD AT LIFESTARS AWARDS™ LIFE SCIENCES 2018 EVENT

November 12, 2018

HARPOON THERAPEUTICS ANNOUNCES CLOSING OF $70M SERIES C FINANCING

September 25, 2018

VERASTEM ONCOLOGY RECEIVES FDA APPROVAL OF COPIKTRA™ (DUVELISIB)

CAPSULES

TREATMENT FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) AFTER AT LEAST TWO PRIOR THERAPIES

September 13, 2018

MPM CAPITAL EXPANDS ITS TEAM OF EXECUTIVE PARTNERS AND ENTREPRENEURS WITH THE APPOINTMENTS OF BIOTECH LEADERS DETLEV BINISZKIEWICZ AND

SCOTT CHAPPEL

September 12, 2018

MPM CAPITAL AND VERSANT VENTURES LAUNCH CODA BIOTHERAPEUTICS TO ACCELERATE DEVELOPMENT OF CHEMOGENETIC GENE THERAPY PLATFORM INDUSTRY VETERAN MICHAEL NARACHI JOINS AS PRESIDENT AND CEO

September 6, 2018

TWENTYEIGHT-SEVEN THERAPEUTICS LAUNCHES WITH A $65 MILLION SERIES A

FUNDING

August 6, 2018

HARPOON THERAPEUTICS TREATS FIRST PATIENT WITH HPN424 IN PHASE 1 CLINICAL TRIAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

(MCRPC) PATIENTS

HPN424, FIRST-IN-CLASS TRITAC™ T CELL REDIRECTION THERAPY, TARGETS PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)

August 1, 2018

ONCORUS®, INC., NAMES INDUSTRY VETERAN TED ASHBURN AS NEW PRESIDENT

AND CEO

– COMPANY CO-FOUNDER MITCH FINER NAMED NEW CHAIRMAN OF THE BOARD –

July 18, 2018

MAVERICK THERAPEUTICS ADVANCES TECHNOLOGY; ADDS KEY MANAGEMENT JAMES R. VASSELLI MD TO LEAD CLINICAL DEVELOPMENT

June 27, 2018

MPM EXECUTIVE PARTNER, DAVID HALLAL, APPOINTED CHAIRMAN OF ITEOS

THERAPEUTICS

June 26, 2018

PATRICK BAEUERLE, MPM EXECUTIVE PARTNER AND IMMUNOTHERAPY PIONEER, TO PRESENT COMPELLING DATA FROM HARPOON THERAPEUTICS’ BIOTHERAPEUTICS PLATFORM AT THE 2018 EUROPEAN CONGRESS ON BIOTECHNOLOGY

June 20, 2018

MPM LEADS $75 MILLION SERIES B FINANCING OF ITEOS THERAPEUTICS

May 29, 2018

CHRIS BARDON TALKS TO WSJ PRO VC ABOUT LATE-STAGE COMBINATION THERAPY

TRIALS

May 22, 2018

MPM CANCER RESEARCH PARTNERSHIP WITH AACR FEATURED IN MEDPAGE TODAY AACR VENTURES INTO NEW CANCER RESEARCH FUNDING MODEL—ADAPTING MODEL PIONEERED BY CYSTIC FIBROSIS FOUNDATION

May 10, 2018

MPM PORTFOLIO COMPANY SEMMA THERAPEUTICS APPOINTS BASTIANO SANNA, PH.D. AS CEO AND PRESIDENT

May 5, 2018

CHRIS BARDON COMMENTS TO REUTERS ON THE OIF AND ITS PHILANTHROPIC

IMPACT

READ: “EXECUTIVE PERSPECTIVE: AN EXAMPLE OF INNOVATIVE IMPACT INVESTING FROM UBS”

May 2, 2018

WATCH NOW: CHRIS BARDON IS A FEATURED PANELIST AT PAYING FOR CURES – GLOBAL CONFERENCE 2018 | MILKEN INSTITUTE

April 23, 2018

MPM’S APPROACH TO INVESTING IS POSITIVELY IMPACTING CANCER RESEARCH

AND CARE

LEARN MORE IN BIOWORLD ARTICLE, “SOCIALLY CONSCIOUS INVESTING BENEFITS AACR, UBS’ OPTIMUS”

April 19, 2018

MPM’S PARTNERSHIP WITH AACR HIGHLIGHTED IN WSJ PRO VC “GORMLEY’S TAKE: HEALTH-CARE INVESTORS DOING GOOD AFTER DOING WELL”

April 18, 2018

MPM CAPITAL PORTFOLIO COMPANY TETHEREX PHARMACEUTICALS COMPLETES $50M

SERIES B FINANCING

April 16, 2018

MPM AND AACR ANNOUNCE PARTNERSHIP IN CANCER RESEARCH

April 16, 2018

WATCH NOW: PRESS EVENT ANNOUNCING MPM AND AACR PARTNERSHIP IN CANCER

RESEARCH

PANEL FROM AACR, MPM AND UBS DISCUSS FIRST FUNDING GIFT FROM UBS ONCOLOGY IMPACT FUND MANAGED BY MPM

April 16, 2018

MPM AND AACR PARTNERSHIP FEATURED IN BARRON’S ARTICLE “UBS ONCOLOGY IMPACT FUND ANNOUNCES $2.5M IN GIFTS”

April 15, 2018

WATCH NOW: CHRIS BARDON ANNOUNCES MPM AND AACR PARTNERSHIP IN CANCER RESEARCH AT AACR 2018 OPENING CEREMONY

April 9, 2018

MPM’S CHRIS BARDON COMMENTS ON LESSONS LEARNED FROM RECENT IO TRIAL

RESULTS

READ BIOWORLD ARTICLE “EPACADOSTAT/KEYTRUDA PIVOTAL TRIAL FLOP SENDS SHIVERS DOWN IDO PATHWAY”

March 21, 2018

MPM PORTFOLIO COMPANY TCR2 THERAPEUTICS RAISES $125 MILLION IN OVERSUBSCRIBED SERIES B FINANCING

February 20, 2018

CULLINAN ONCOLOGY AND MAB DISCOVERY ANNOUNCE COLLABORATION TO DEVELOP NOVEL ANTIBODY-BASED THERAPEUTICS

January 24, 2018

ASTELLAS COMPLETES ACQUISITION OF MITOBRIDGE, INC.

January 11, 2018

BIOWORLD’S KEY HIGHLIGHTS FROM THE WOMEN IN BIO AND BLOOMBERG INTELLIGENCE PANEL WITH CHRIS BARDON AT JPM18 “WOMEN HAVE THEIR SAY AS ALL-FEMALE PANEL TALKS BIOPHARMA INVESTMENT, TECHNOLOGY TRENDS”

January 10, 2018

SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN

BREAST CANCER

January 9, 2018

WATCH NOW: CHRIS BARDON DISCUSSES THE CYCLE OF INNOVATION AND VALUE OF TRANSFORMATIVE THERAPIES ON CNBC

January 9, 2018

RHYTHM PHARMACEUTICALS ENTERS INTO PARTNERSHIP WITH WUXI NEXTCODE THE EMERGING GLOBAL STANDARD PLATFORM FOR GENOMIC DATA THE PARTNERSHIP WILL HELP RHYTHM IDENTIFY GENETIC MARKERS FOR RARE METABOLIC SYNDROMES AND OPTIMIZE INVESTIGATIONAL COMPOUNDS

January 8, 2018

CHRIS BARDON SHARES HER THOUGHTS ON MARKET TRENDS AND INNOVATIVE THERAPIES WITH BIOWORLD “‘SPIRIT’ OF JPM LIVES ON AS OTHER MEETINGS MUSCLE IN ON BIOPHARMA PLAYGROUND”

January 3, 2018

TCR2 THERAPEUTICS TO PRESENT AT THE 36TH ANNUAL J.P. MORGAN HEALTHCARE

CONFERENCE

*

2017

December 9, 2017

CHRIS BARDON COMMENTS ON POSITIVE GENE THERAPY DATA IN FORBES ARTICLE, “EXCITEMENT BUILDS AROUND GENE THERAPY CURES FOR HEMOPHILIA”

December 1, 2017

MPM PORTFOLIO COMPANY, MITOBRIDGE, INC. TO BE ACQUIRED BY ASTELLAS PHARMACEUTICALS IN A DEAL WORTH UP TO $450 MILLION

November 30, 2017

SEMMA THERAPEUTICS RAISES $114M FOR NOVEL DIABETES TREATMENT

October 19, 2017

SYNDAX EXPANDS PIPELINE WITH EXCLUSIVE WORLDWIDE LICENSE TO ALLERGAN’S PORTFOLIO OF MENIN-MLL INHIBITORS

October 19, 2017

TCR2 THERAPEUTICS APPOINTS LEADING CELL THERAPY EXPERT AS CHIEF

MEDICAL OFFICER

October 19, 2017

BLADE THERAPEUTICS ANNOUNCES SELECTION OF A CLINICAL DEVELOPMENT CANDIDATE AND FUNDING OF THE SECOND TRANCHE FOR ITS SERIES B FINANCING

October 18, 2017

ABBVIE AND HARPOON THERAPEUTICS ANNOUNCE IMMUNO-ONCOLOGY RESEARCH

COLLABORATION

October 17, 2017

MITOBRIDGE FEATURED IN BLOOMBERG ARTICLE, “ONE SCIENTIST’S MARATHON QUEST FOR THE EXERCISE PILL”

October 4, 2017

RHYTHM PHARMACEUTICALS, INC. ANNOUNCES PRICING OF INITIAL PUBLIC

OFFERING

October 3, 2017

ONCORUS®, INC., NAMES CHRISTOPHE QUÉVA, PH.D., AS CHIEF SCIENTIFIC

OFFICER

October 3, 2017

THE UBS ONCOLOGY IMPACT FUND CO-LEADS $150 MILLION SERIES A FINANCING OF CULLINAN ONCOLOGY CULLINAN ONCOLOGY IS AN INNOVATIVE DEVELOPMENT COMPANY WITH AN ACCOMPLISHED MANAGEMENT TEAM TO DEVELOP PIPELINE OF NOVEL CANCER

THERAPIES

September 26, 2017

REPARE THERAPEUTICS NAMED AS ONE OF FIERCEBIOTECH’S “FIERCE 15” BIOTECH COMPANIES OF 2017

September 16, 2017

INSIDE PERSPECTIVES ON GENE EDITING: AN INTERVIEW WITH MPM CAPITAL’S

MITCHELL FINER

September 15, 2017

TCR2 THERAPEUTICS NAMED ONE OF THE 15 INNOVATIVE IMMUNO-ONCOLOGY BIOTECHS TO WATCH IN 2018 BY IMMUNO-ONCOLOGY FRONTIERS

September 13, 2017

ONCORUS’ VIRAL CANCER VACCINE HIGHLIGHTED IN WSJ: “SCIENTISTS SEE PROGRESS FOR CANCER VACCINES”

September 5, 2017

INSIDE PERSPECTIVES ON CANCER IMMUNOTHERAPY: AN INTERVIEW WITH MPM’S

CHRISTIANA BARDON

September 1, 2017

GORMLEY’S TAKE: WRITING WAR ON CANCER’S NEXT CHAPTER –– BIOTECH STARTUPS SEEK TO WIDEN BENEFITS OF REVOLUTIONARY CELL-THERAPY

TREATMENTS

WSJ PRO VENTURE CAPITAL FEATURES MPM’S CHRIS BARDON

AND TCR2

August 31, 2017

MPM’S CHRIS BARDON APPLAUDS NOVARTIS’ VALUE-BASED PRICING MOVE FOR ITS CAR-T CELL THERAPY KYMRIAH READ BIOWORLD ARTICLE “GENE THERAPY, CLOAKED IN CELL THERAPY, ARRIVES IN U.S. COURTESY OF KYMRIAH”

August 11, 2017

MAVERICK THERAPEUTICS APPOINTS JAMES S. SCIBETTA AS CEO

July 27, 2017

MPM’S CHRIS BARDON TALKS TO BIOWORLD ABOUT RECENT PHARMA R&D

RESTRUCTURING

TRENDS POINT TO PHARMA FOCUS ON SIGNING MORE EARLY STAGE PARTNERSHIPS

July 17, 2017

RADIUS HEALTH APPOINTS JESPER HØILAND AS PRESIDENT AND CHIEF

EXECUTIVE OFFICER

LEADING THE NEXT STAGE OF GROWTH AND VALUE CREATION AS A FULLY INTEGRATED COMMERCIAL BIOTECH COMPANY

June 28, 2017

SEMMA THERAPEUTICS MENTIONED IN WSJ ARTICLE “BIOTECH STARTUPS’ CELL-BASED DIABETES ATTACK”

June 22, 2017

MPM AND VERSANT VENTURE CO-LEAD SERIES A FINANCING OF REPARE

THERAPEUTICS

June 21, 2017

PROTEON THERAPEUTICS ANNOUNCES $22.0 MILLION PRIVATE PLACEMENT

June 20, 2017

VISIONARY SCIENTIST STEPHEN J. ELLEDGE JOINS MPM CAPITAL’S MEDICAL AND SCIENTIFIC ADVISORY BOARD

June 13, 2017

ACCOMPLISHED ONCOLOGIST AND SCIENTIST WILLIAM C. HAHN JOINS MPM CAPITAL’S ONCOLOGY IMPACT FUND ADVISORY BOARD

June 8, 2017

TCR2 THERAPEUTICS TO DEBUT POSITIVE SOLID TUMOR DATA ON ITS NOVEL TRUC™ ENGINEERED T CELL PLATFORM AT THE WORLD PRECLINICAL CONGRESS

June 6, 2017

RADIUS PRESENTS POSITIVE DATA FROM A FULLY ENROLLED ONGOING PHASE I STUDY FOR INVESTIGATIONAL DRUG ELACESTRANT (RAD1901) AT THE 2017 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING (ASCO)

May 25, 2017

AMGEN VET PATRICK BAEUERLE INSPIRES A $45M ROUND FROM A-LIST VCS FOR A NEXT-GEN I/O DRUG PLATFORM

May 25, 2017

HARPOON THERAPEUTICS ANNOUNCES COMPLETION OF $45M SERIES B FINANCING

May 23, 2017

MPM PORTFOLIO COMPANY TRUE NORTH THERAPEUTICS ACQUIRED BY BIOVERATIV,

INC

UPFRONT PAYMENT OF $400M PLUS ASSUMED CASH, WITH ADDITIONAL PAYMENTS OF UP TO $425M CONTINGENT ON THE ACHIEVEMENT OF FUTURE MILESTONES

May 18, 2017

SYNDAX SHARES SOAR AS LEAD DRUG CLEARS A MID-STAGE CANCER DRUG STUDY

HURDLE

May 4, 2017

CONATUS ANNOUNCES EXERCISE OF LICENSE OPTION FOR GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF EMRICASAN FOLLOWING NOTICE OF INITIATION OF PHASE 2B ENCORE-LF CLINICAL TRIAL IN NASH CIRRHOSIS

May 3, 2017

INSIDE PERSPECTIVES ON CANCER IMMUNOTHERAPY: AN INTERVIEW WITH MPM’S

CHRISTIANA BARDON

April 28, 2017

FDA APPROVES MPM PORTFOLIO COMPANY RADIUS HEALTH’S TYMLOS™

(ABALOPARATIDE)

BONE BUILDING AGENT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE

April 17, 2017

MEET ONE THE MOST SUCCESSFUL GERMAN BIOTECH LEADERS EVER READ MORE ABOUT MPM’S PATRICK BAEUERLE

April 5, 2017

MPM MANAGING DIRECTOR CHRIS BARDON NAMED A TOP-40 TRANSFORMER TOP INNOVATION GURUS LEADING THE BIOPHARMA INDUSTRY'S TRANSFORMATION ARE RECOGNIZED BY MM&M

April 4, 2017

MPM PORTFOLIO COMPANY ONCORUS NOMINATED FOR 2017 NEVY AWARD AS HOTTEST EARLY-STAGE STARTUP THERAPEUTICS

April 4, 2017

SYNDAX PHARMACEUTICALS ADDS BIOPHARMACEUTICAL INDUSTRY LEADER KEITH A. KATKIN TO BOARD OF DIRECTORS

February 16, 2017

RHYTHM ANNOUNCES COMPLETION OF $41 MILLION MEZZANINE FINANCING — PROCEEDS TO FINANCE SIGNIFICANT EXPANSION OF GENETIC OBESITY

CLINICAL TRIALS —

February 7, 2017

CHRIS VARMA, CO-FOUNDER AND FORMER PRESIDENT AND CEO OF BLUEPRINT MEDICINES, JOINS MPM AS ENTREPRENEUR-IN-RESIDENCE

January 11, 2017

MPM PORTFOLIO COMPANY MAVERICK THERAPEUTICS AND TAKEDA ANNOUNCE FIVE-YEAR COLLABORATION TO ADVANCE T-CELL ENGAGEMENT THERAPIES

January 5, 2017

ACCOMPLISHED BIOTECH INVESTOR ED HURWITZ JOINS MPM AS MANAGING

DIRECTOR

*

2016

December 19, 2016

MPM PORTFOLIO COMPANY, ASTUTE MEDICAL, FORMS STRATEGIC PARTNERSHIP

WITH BIO-TECHNE

December 19, 2016

NOVARTIS SIGNS EXCLUSIVE OPTION, COLLABORATION AND LICENSE AGREEMENT WITH MPM PORTFOLIO COMPANY CONATUS PHARMACEUTICALS INC.

December 15, 2016

ONCORUS®, INC. ANNOUNCES ADDITIONAL SERIES A FINANCING SUPPORT FROM ASTELLAS VENTURE MANAGEMENT LLC

December 13, 2016

HARPOON THERAPEUTICS APPOINTS GERALD MCMAHON, PH.D., AS PRESIDENT AND

CEO

December 8, 2016

TCR2 THERAPEUTICS LAUNCHES FROM STEALTH MODE TO ACCELERATE DEVELOPMENT OF NOVEL CANCER IMMUNOTHERAPIES - $44.5M SERIES A FINANCING LED BY MPM CAPITAL AND F2 VENTURES -

December 2, 2016

CHRIS BARDON, MPM MANAGING DIRECTOR, COMMENTS TO BLOOMBERG ON NEW APPROACHES TO MEDICAL PHILANTHROPY READ FULL ARTICLE – “A FEW BILLIONAIRES ARE TURNING MEDICAL PHILANTHROPY ON ITS HEAD”

November 28, 2016

EPIZYME ANNOUNCES FAST TRACK DESIGNATION FOR TAZEMETOSTAT IN DLBCL AND PROVIDES TUMOR PROGRAM UPDATE

November 21, 2016

NOVARTIS ACQUIRES MPM PORTFOLIO COMPANY SELEXYS PHARMACEUTICALS CORPORATION AND SELG1 ANTIBODY FOR REDUCTION OF PAIN CRISES IN SICKLE

CELL DISEASE

November 8, 2016

HARPOON THERAPEUTICS APPOINTS HANS-PETER GERBER, PHD, AS CHIEF

SCIENTIFIC OFFICER

November 7, 2016

SEMMA THERAPEUTICS ANNOUNCES MARK FISHMAN, M.D. HAS JOINED ITS BOARD OF DIRECTORS AS CHAIRMAN

October 31, 2016

MPM PORTFOLIO COMPANY EPIZYME EXPANDS CLINICAL PROGRAMS THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTS WITH THE NATIONAL

CANCER INSTITUTE

October 27, 2016

MOTUS THERAPEUTICS INC., A SUBSIDIARY OF MPM PORTFOLIO COMPANY RHYTHM HOLDING CO., LLC IS TO BE ACQUIRED BY ALLERGAN ACQUISITION ANNOUNCED FOLLOWING POSITIVE RESULTS FOR PHASE 2B CLINICAL TRIAL OF TREATMENT FOR GI DISORDERS

October 13, 2016

TRUE NORTH THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR TNT009 FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA, INCLUDING COLD AGGLUTININ DISEASE (CAD)

October 11, 2016

PACIRA PHARMACEUTICALS’ KRISTEN WILLIAMS IS HONORED AS 1 OF 15 “FIERCE WOMEN IN BIOPHARMA 2016” LEARN WHY KRISTEN STANDS OUT AMONG WOMEN IN THE INDUSTRY

September 22, 2016

IOMX THERAPEUTICS RAISES EUR 40 MILLION IN SERIES A ROUND COMPANY ESTABLISHES TOP-TIER INVESTOR BASE CONSISTING OF MPM CAPITAL, SOFINNOVA PARTNERS, WELLINGTON PARTNERS AND MERCK VENTURES

September 19, 2016

THREE MPM PORTFOLIO COMPANIES (BLADE, ONCORUS & RHYTHM) NAMED TO FIERCEBIOTECH’S “2016 FIERCE 15” LIST

September 19, 2016

RADIUS ANNOUNCES PUBLICATION OF ADDITIONAL POSITIVE RESULTS FROM THE PHASE 3 ACTIVE TRIAL OF OSTEOPOROSIS TREATMENT

September 14, 2016

TIZONA THERAPEUTICS, INC. APPOINTS GEORGE GOLUMBESKI, PH.D., TO ITS

BOARD OF DIRECTORS

August 16, 2016

OSTEOPOROSIS, A DISEASE WITH FEW TREATMENT OPTIONS, MAY SOON HAVE ONE

MORE

READ COVERAGE IN NY TIMES AND IN PRESS RELEASE

August 15, 2016

ARATANA

SECURES THIRD FDA APPROVAL ANIMAL PAIN DRUG EXPECTED TO BE AVAILABLE TO VETERINARIANS IN THE FALL

OF 2016

August 11, 2016

HARVARD MEDICAL SCHOOL APPOINTS MPM MEDICAL AND SCIENTIFIC ADVISORY CO-CHAIR GEORGE DALEY AS NEW DEAN READ MORE IN THE BOSTON GLOBE

August 10, 2016

ICONIC THERAPEUTICS ANNOUNCES FINAL CLOSE OF SERIES C FINANCING WITH ADDITIONAL $10 MILLION INVESTMENT

August 1, 2016

ASTELLAS AND MPM CAPITAL LAUNCH DIGITX PARTNERS

July 26, 2016

MPM PORTFOLIO COMPANY BLADE THERAPEUTICS FEATURED IN THE SAN FRANCISCO

BUSINESS TIMES

THE JULY 19 ARTICLE, “TAKING IT PERSONALLY, CUTTING–EDGE BIOTECH SNAGS $45 MILLION,” DISCUSSES THE LATEST ROUND OF FUNDING FOR BLADE, A COMPANY FOCUSED ON FINDING THERAPIES FOR FIBROTIC DISEASE, AND MPM CO-FOUNDER LUKE EVNIN’S PERSONAL COMMITMENT TO THE CAUSE.

July 21, 2016

RHYTHM ANNOUNCES NEW ENGLAND JOURNAL OF MEDICINE PUBLICATION OF SETMELANOTIDE PHASE 2 DATA FOR TREATMENT OF POMC DEFICIENCY OBESITY SIGNIFICANT WEIGHT LOSS WITH TARGETED TREATMENT FOR PATIENTS WITH RARE GENETIC DEFECT IN CRITICAL WEIGHT REGULATION PATHWAY

July 20, 2016

FORMER BLUEBIRD BIO (BLUE) CSO TAKES THE REINS AT ONCORUS; STARTUP LAUNCHES WITH $57 MILLION SERIES A

June 16, 2016

MPM PORTFOLIO COMPANY SEMMA THERAPEUTICS FEATURED IN BOSTON GLOBE BOSTON-AREA HOSPITALS HAVE TEAMED UP WITH THE HARVARD STEM CELL INSTITUTE AND SEMMA THERAPEUTICS TO MAKE PERSONALIZED CELL-BASED THERAPIES AND ORGANIZE CLINICAL TRIALS.

June 2, 2016

CHRIS BARDON, MANAGING DIRECTOR FOR THE ONCOLOGY IMPACT FUND, ON BLOOMBERG CAPITAL MARKETS DISCUSSING ADVANCES IN CANCER THERAPIES AS THE 2016 ASCO ANNUAL MEETING GETS UNDERWAY

May 27, 2016

TRINETX ENTERS INTO COLLABORATION WITH CELGENE ADVANCE CLINICAL TRIAL DESIGN AND RESEARCH FOR NEXT-GENERATION

MEDICINES PLANNED

May 18, 2016

ARATANA THERAPEUTICS GRANTED FDA APPROVAL OF ENTYCE® FIRST-OF-ITS-KIND GHRELIN MIMETIC

May 3, 2016

MPM LAUNCHES $471 MILLION SOCIAL IMPACT ONCOLOGY FUND

April 29, 2016

UBS CANCER FUND SHOWS POWER OF IMPACT INVESTING A NEW ONCOLOGY FUND WILL FINANCE ACADEMIC RESEARCH AND ACCESS TO CANCER CARE IN DEVELOPING COUNTRIES

April 28, 2016

UBS, MPM SEEK BIG ‘IMPACT’ IN CANCER DRUGS WITH $471M FUND BY MARIE POWERS, BIOWORLD TODAY, APRIL 28, 2016

April 27, 2016

UBS RAISES RECORD $471 MILLION FOR ONCOLOGY IMPACT FUND BIOSPACE.COM 4/27/2016

March 21, 2016

ARATANA THERAPEUTICS GRANTED FIRST FDA APPROVAL GALLIPRANT FOR THE CONTROL OF PAIN AND INFLAMMATION ASSOCIATED WITH OSTEOARTHRITIS IN DOGS

March 14, 2016

CHIASMA INITIATES PHASE 3 TRIAL TO SUPPORT EUROPEAN REGISTRATION OF OCTREOTIDE CAPSULES FOR PATIENTS WITH ACROMEGALY

March 8, 2016

TIZONA THERAPEUTICS, INC., COMPLETES $43 MILLION SERIES B FINANCING

March 6, 2016

RADIUS HEALTH SUBMITS NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR ABALOPARATIDE-SC FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

March 3, 2016

NASDAQ WELCOMES SYNDAX PARMACEUTICALS, INC. TO THE NASDAQ STOCK MARKET

January 9, 2016

ICONIC THERAPEUTICS CLOSES SERIES C FINANCING

*

2015

October 15, 2015

SEMMA THERAPEUTICS NAMED FIERCEMEDICALDEVICES’ 2015 FIERCE 15

August 27, 2015

SYNDAX ENTERS CLINICAL TRIAL COLLABORATION IN CANCER IMMUNOTHERAPY COMBINING ENTINOSTAT AND ATEZOLIZUMAB

August 24, 2015

SYNDAX RAISES $80 MILLION IN SERIES C FINANCING

August 17, 2015

RHYTHM SUBSIDIARY RAISES $40 MILLION IN OVERSUBSCRIBED FINANCING FINANCING TO ADVANCE RHYTHM METABOLIC, INC.'S SETMELANOTIDE PROGRAM FOR RARE GENETIC DISORDERS OF OBESITY

August 15, 2015

EPIZYME APPOINTS ROBERT BAZEMORE PRESIDENT AND CHIEF EXECUTIVE OFFICER

July 16, 2015

CHIASMA, INC. PRICES INITIAL PUBLIC OFFERING OF COMMON STOCK

July 10, 2015

TAKING CLINICAL TRIALS OUT OF THE DARK AGES (CLINICAL INK)

June 23, 2015

BRIGGS W. MORRISON, M.D., CEO OF SYNDAX, APPOINTED KEY STRATEGIC ADVISOR TO MPM CAPITAL

June 15, 2015

CHIASMA SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR OCTREOTIDE CAPSULES IN ACROMEGALY SUBMISSION BASED ON POSITIVE RESULTS FROM PHASE 3 CLINICAL TRIAL

June 1, 2015

K. PETER HIRTH, PHD, JOINS ICONIC THERAPEUTICS AS BOARD MEMBER AND SENIOR SCIENTIFIC ADVISOR

May 21, 2015

MPM CAPITAL APPOINTS PABLO J. CAGNONI, M.D., FORMER ONYX PHARMACEUTICALS PRESIDENT, AS MANAGING DIRECTOR AND CEO OF MPM IMMUNOTHERAPY PORTFOLIO COMPANY VESUVIUS

May 14, 2015

MPM CLOSES $400 MILLION FUND

May 5, 2015

23ANDME LAUNCHES THE LUPUS RESEARCH STUDY IN COLLABORATION WITH PFIZER

INC.

WITH LUPUS AWARENESS MONTH UNDERWAY, STUDY AIMS TO BUILD A 5,000-PATIENT LUPUS COHORT TO ADVANCE UNDERSTANDING OF THE DISEASE

April 22, 2015

ASTELLAS PHARMA AND POTENZA THERAPEUTICS PARTNER TO BUILD A PORTFOLIO OF IMMUNO-ONCOLOGY THERAPEUTICS EXCLUSIVE COLLABORATION INCLUDES OPTION FOR ASTELLAS TO ACQUIRE

POTENZA

April 15, 2015

NOVARTIS INTERNATIONAL GLOBAL HEAD M&A AND LICENSING ANTHONY ROSENBERG TO JOIN AS MANAGING DIRECTOR, EFFECTIVE APRIL 1, 2015 - TO SERVE AS STRATEGIC ADVISOR AND ON MPM PORTFOLIO BOARDS TO BUILD

LEADING COMPANIES -

March 24, 2015

BIOTECH STARTUP TO FIGHT DIABETES ON THE CELLULAR FRONT SEMMA THERAPEUTICS SEEKS TO TURN SUCCESS IN STEM RESEARCH LAB INTO A WAY TO ENCOURAGE INSULIN PRODUCTION

March 24, 2015

SEMMA THERAPEUTICS ANNOUNCES $44 MILLION IN FUNDING LED BY MPM CAPITAL TO DEVELOP CELL THERAPY FOR TREATING TYPE 1 DIABETES; SIGNS AGREEMENT WITH GLOBAL PHARMACEUTICAL COMPANY

March 16, 2015

EBB & FLOW: CHIASMA’S PRIVATE DECISION

March 16, 2015

CHIASMA ANNOUNCES MARK LEUCHTENBERGER AS CHIEF EXECUTIVE OFFICER PROVEN BUSINESS LEADER TO OVERSEE COMMERCIALIZATION OF OCTREOTIDE

CAPSULES

March 12, 2015

23ANDME TO CREATE THERAPEUTICS GROUP, APPOINTS SCIENTIFIC LUMINARY, R&D EXECUTIVE RICHARD SCHELLER, PH.D. TO LEAD DR. SCHELLER JOINS 23ANDME’S EXECUTIVE LEADERSHIP TEAM AS CHIEF SCIENCE OFFICER AND HEAD OF THERAPEUTICS

March 11, 2015

MPM CAPITAL ANNOUNCES IMMUNO-ONCOLOGY PIONEER PATRICK BAEUERLE TO SERVE AS MANAGING DIRECTOR -TOP SCIENTIST AND DRUG DEVELOPER JOINS MPM SENIOR TEAM ADVANCING BREAKTHROUGHS AND DISCOVERIES

March 10, 2015

RADIUS (RDUS) ANNOUNCED TODAY THAT IT HAS ACQUIRED THE LICENSE TO DEVELOP AND MARKET RAD1901 IN JAPAN DINESH PURANDARE HIRED (FORMER SANOFI (SAN.PA) ONCOLOGY EXECUTIVE TO THE POSITION OF SENIOR VICE PRESIDENT (SVP) AND HEAD OF GLOBAL ONCOLOGY AT RADIUS )

February 27, 2015

CHIASMA ANNOUNCES COMPLETION OF $70 MILLION SERIES E FINANCING

February 27, 2015

VERASTEM RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR VS-5584 IN

MESOTHELIOMA

February 24, 2015

CHIASMA APPOINTS DAVID STACK AS CHAIRMAN OF THE BOARD; JOHN A. SCARLETT, M.D. JOINS BOARD OF DIRECTORS

February 20, 2015

SYNDAX SAYS IMMUNO-ONCOLOGY DISCOVERY HAPPENED INSTEAD OF AN IPO

February 10, 2015

CHIASMA INC. RELEASES NEWLY PUBLISHED PHASE 3 STUDY RESULTS SHOW POSITIVE OUTCOMES FOR OCTREOTIDE CAPSULES IN PEOPLE WITH ACROMEGALY, A SERIOUS HORMONAL DISORDER

February 9, 2015

RADIUS, CELLADON AND NEVRO AMONG TOP IPOS IN 2014 MPM HAS #1, 8 AND 10 OUT OF THE TOP 14

January 1, 2015

RADIUS: THE TOP PERFORMING IPO OF 2014 RADIUS, WHICH IS DEVELOPING TREATMENTS FOR OSTEOPOROSIS, IS UP 364% SINCE PRICING ITS JUNE 6 INITIAL PUBLIC OFFERING AT 8

*

2014

December 22, 2014

RADIUS ANNOUNCES POSITIVE PHASE 3 TOP-LINE RESULTS

December 15, 2014

FOR VENTURE CAPITAL, BIOTECH IS WHERE IT’S REALLY AT

August 4, 2014

ARATANA FEATURED: START-UPS WORK ON BIOTECH DRUGS FOR PETS

June 17, 2014

TRUE NORTH SNAGS $22M AND SETS COURSE FOR THE CLINIC WITH A RARE

DISEASE DRUG

April 29, 2014

IPIERIAN ACQUIRED BY BRISTOL-MYERS SQUIBB ADVANCES DISCOVERY STRATEGY TO PURSUE THERAPEUTICS FOR GENETICALLY

DEFINED DISEASES

April 16, 2014

ICONIC THERAPEUTICS RAISES $20 MILLION TO ADVANCE CLINICAL DEVELOPMENT

OF WET AMD PROGRAM

WILLIAM GREENE, MD, APPOINTED CHIEF EXECUTIVE OFFICER

April 14, 2014

CELLADON RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA MYDICAR IS FIRST GENE THERAPY REPORTED TO RECEIVE BREAKTHROUGH DESIGNATION FROM FDA’S CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

(CBER)

February 18, 2014

COSTIM PHARMACEUTICALS, INC. ACQUIRED BY NOVARTIS

January 27, 2014

MPM CAPITAL AND KLEINER PERKINS CAUFIELD & BYERS TOP THE LIST OF INVESTORS WITH THE MOST 2013 IPOS

January 7, 2014

EPIZYME AND CELGENE ADVANCE EPZ-5676 DOT1L INHIBITOR CLINICAL PROGRAM TO BENEFIT CANCER PATIENTS WITH ACUTE LEUKEMIAS, ACHIEVING $25 MILLION CLINICAL PROOF OF CONCEPT MILESTONE

*

*

back to top

Copyright © 2020 MPM Capital, Inc.

X

X

X

Please click here for all funds: Investor Login

X